FDA pre-sub meetings, EMA Scientific Advice, and PMDA consultations designed to de-risk classification and approval pathways before you invest in clinical trials.

‍

Expert navigation of FDA OCP jurisdictional determinations (21 CFR Part 4) and EU MDR Article 117 classifications, leveraging our team's experience from both sides of the regulatory table.

End-to-end preparation and submission management for US 510(k)/PMA/BLA, EU MDR Technical Documentation, and Health Canada MDEL pathways, with former Notified Body members ensuring first-submission approval.

Simultaneous multi-market submission strategies that prevent delays by designing FDA and MDR requirements in parallel from day one.